Gefitinib
- Generic Name
- Gefitinib
- Brand Names
- Iressa, Gefitinib Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C22H24ClFN4O3
- CAS Number
- 184475-35-2
- Unique Ingredient Identifier
- S65743JHBS
- Background
Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa.
- Indication
For the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies.
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer
- Associated Therapies
- -
BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-07-14
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 41
- Registration Number
- NCT00352079
- Locations
- 🇨🇦
Clinical Research Unit at Vancouver Coastal, Vancouver, British Columbia, Canada
🇨🇦CHUQ-Pavillon Hotel-Dieu de Quebec, Quebec City, Quebec, Canada
🇨🇦Centre hospitalier universitaire de Sherbrooke, Sherbrooke, Quebec, Canada
First-line Treatment for Adenocarcinoma Patients With Epidermal Growth Factor Receptor (EGFR) Mutation
- First Posted Date
- 2006-06-27
- Last Posted Date
- 2010-06-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 46
- Registration Number
- NCT00344773
- Locations
- 🇰🇷
Research Site, Seoul, Korea, Republic of
Phase II Iressa + Irradiation Followed by Chemo in NSCLC
- Conditions
- First Posted Date
- 2006-06-05
- Last Posted Date
- 2007-12-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 50
- Registration Number
- NCT00333294
- Locations
- 🇫🇷
Research Site, Nantes, France
🇫🇷Research SIte, Paris, France
First Line IRESSA™ Versus Carboplatin/Paclitaxel in Asia
- Conditions
- Interventions
- First Posted Date
- 2006-05-08
- Last Posted Date
- 2013-11-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1329
- Registration Number
- NCT00322452
- Locations
- 🇹🇭
Research Site, Songkla, Thailand
Second-Line Irinotecan or Gefitinib in Docetaxel Pretreated NSCLC
- Conditions
- First Posted Date
- 2006-04-27
- Last Posted Date
- 2008-03-12
- Lead Sponsor
- Gachon University Gil Medical Center
- Target Recruit Count
- 50
- Registration Number
- NCT00319800
- Locations
- 🇰🇷
Gachon University Gil Medical Center, Incheon, Korea, Republic of
Combination Weekly Taxotere™ With Iressa™ /Placebo in Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2006-04-27
- Last Posted Date
- 2007-12-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 66
- Registration Number
- NCT00319618
- Locations
- 🇳🇴
Research Site, Oslo, Norway
Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-04-25
- Last Posted Date
- 2022-02-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 19
- Registration Number
- NCT00317772
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Gefitinib, Docetaxel, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2006-04-03
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 45
- Registration Number
- NCT00310154
- Locations
- 🇺🇸
Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
A Study of IRESSA in Relapsed and Refractory Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2006-03-03
- Last Posted Date
- 2008-06-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 56
- Registration Number
- NCT00298688
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
Gefitinib, Cisplatin, Irinotecan, and Radiation Therapy Before Surgery in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer That Can Be Removed By Surgery
- Conditions
- First Posted Date
- 2006-02-13
- Last Posted Date
- 2014-05-09
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 6
- Registration Number
- NCT00290719
- Locations
- 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.